Compare ARMOUR Residential REIT, Inc. (ARR) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARMOUR Residential REIT, Inc. vs Tenet Healthcare Corporation — how do they compare? ARMOUR Residential REIT, Inc. trades at $16.71 (market cap $2.05B), while Tenet Healthcare Corporation trades at $260.39 (market cap $20.93B). The key difference: Tenet Healthcare Corporation is far larger — about 10.2× ARMOUR Residential REIT, Inc.'s market cap, and ARMOUR Residential REIT, Inc. pays a 17.41% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals.
| ARR | THC | |
|---|---|---|
Market Cap | $2.05B | $20.93B |
Sector | Financials | Health |
52-Week High | $19.12 | $262.63 |
52-Week Low | $14.05 | $161.37 |
Dividend Yield | 17.41% | — |
Enterprise Value | — | $32.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARMOUR Residential REIT (ARR) trades at $16.68, up 0.79% with a bullish technical signal despite mixed earnings performance. The REIT shows strong profitability with 97.43% net income margin and 19.74% ROE, trading below book value at P/B of 0.92. Recent quarterly results show alternating beats and misses, with Q2 2026 EPS of $0.72 slightly missing expectations. The company maintains consistent dividend payments of $0.24 quarterly, supporting income investor appeal.
ARR presents a value opportunity with attractive dividend yield but faces earnings volatility and high leverage risks. Analyst consensus is cautious with 60% hold ratings, reflecting concerns about mortgage REIT sensitivity to interest rates. The stock's technical position near key support at $16 suggests near-term stability, but investors should monitor interest rate environment impacts on mortgage-backed securities portfolio performance.
Tenet Healthcare (THC) trades at $262.13, up 2.14% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with Q2 2026 EPS beating estimates at $6.12 versus $4.26 expected, while valuation metrics remain attractive with P/E of 10.05 and EV/EBITDA of 5.74. Recent institutional buying and positive earnings revisions support the upward trend.
Outlook remains positive with consensus price target of $281.44 offering 7.4% upside potential. Key risks include healthcare policy headwinds and competitive pressures, but strong ambulatory growth and expense management provide fundamental support. The stock presents a compelling value-growth combination for investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARMOUR Residential REIT, Inc.
ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.
Read more on ARR →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
